JPRN-UMIN000016373已完成未知
Clinical efficacy of garenoxacin for treatment of bacterial respiratory infection secondary to chronic respiratory disease - GARIREO study
Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University School of Medicine0 个研究点目标入组 120 人开始时间: 2015年1月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet any one of the following criteria will be excluded. 1) Patients with severe infection, for which ambulatory treatment with oral antibacterial drugs is not suitable 2) Patients with infection caused by pathogens for which garenoxacin is considered ineffective 3) Patients whose symptoms improve within 7 days before the start of treatment with garenoxacin 4) Patients who are being treated with other systemic antibacterial drugs (patients being treated with a small-dose long-term treatment with macrolide antibiotics without dosage change are acceptable for registration). 5) Patients who are hypersensitive to or have a history of hypersensitivity to or serious adverse events by quinolone antibacterial drugs. 6) Pregnant or possibly pregnant patients 7) Patients with low body weight (<40 kg) 8) Patients with severe renal function disorder (Ccr <30mL/min) or hepatic function disorder 9) Patients who have received systemic treatment with corticosteroids (prednisolone equivalent dose >10mg/day) (patients who have been treated with inhaled steroids without dosage change are acceptable for registration). 10) Patients who have been registered already. 11) Patients who are deemed inappropriate to participate in the study by investigators/subinvestigators for other reasons.
研究者
相似试验
未知
3 期
Phase III study of Garenoxacin in the treatment of community-acquired pneumonia- A randomized, multi-center, double-blind, double-dummy and comparative studyThe patients with community-acquired pneumoniaJPRN-jRCT2080221655Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
已完成
2 期
Efficacy and safety of Garenoxacin for the prevention in the patients with hematological malignancies after chemotherapyhematological malignanciesJPRN-UMIN000004979Gifu University Hospital50
已完成
不适用
Efficacy and safety of GHX02 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitisKCT0003665Daejeon Korean Medicine Hospital of Daejeon University117
招募中
不适用
Clinical study of Garenoxacin on male non-gonococcal urethritisJPRN-UMIN000014994Jikei university katsushika medical center,Department of urology50
已完成
不适用
Garenoxacin versus Levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiologyJPRN-UMIN000012421Hokuriku otolaryngology practiced expert study group200